What Corcept Therapeutics Incorporated's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 59 | 111 |
| Total trades | 103 | 267 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 357,882 | 3,189,974 |
| Disposed | 497,302 | 3,732,601 |
| Net activity | −139,420 | −542,627 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Wilson James N | Director | Oct 15 | Open-market sale · S | −300 | $116.30 | −$34.9K | 1,054,543 |
| Wilson James N | Director | Oct 15 | Open-market sale · S | −3,046 | $115.39 | −$351K | 1,054,843 |
| Wilson James N | Director | Oct 15 | Open-market sale · S | −6,654 | $114.48 | −$762K | 1,057,889 |
| Vieira Roberto Wandenkolk | President, Oncology | Oct 02 | Open-market sale · S | −5,147 | $116.59 | −$600K | 3,946 |
| Vieira Roberto Wandenkolk | President, Oncology | Oct 02 | Open-market sale · S | −2,086 | $115.73 | −$241K | 9,093 |
| Vieira Roberto Wandenkolk | President, Oncology | Oct 02 | Open-market sale · S | −1,100 | $114.52 | −$126K | 11,179 |
| Vieira Roberto Wandenkolk | President, Oncology | Oct 02 | Exercise / conversion · M | +8,333 | $21.63 | +$180K | 12,279 |
| Lyon Joseph Douglas | See Remarks | Oct 02 | Open-market sale · S | −4,744 | $116.54 | −$553K | 5,683 |
| Lyon Joseph Douglas | See Remarks | Oct 02 | Open-market sale · S | −4,446 | $115.70 | −$514K | 10,427 |
| Lyon Joseph Douglas | See Remarks | Oct 02 | Exercise / conversion · M | +5,833 | $19.26 | +$112K | 14,873 |
| Lyon Joseph Douglas | See Remarks | Oct 02 | Exercise / conversion · M | +3,357 | $13.56 | +$45.5K | 9,040 |
| Maduck Sean | See Remarks | Oct 02 | Open-market sale · S | −8,744 | $116.55 | −$1.02M | 9,938 |
| Maduck Sean | See Remarks | Oct 02 | Open-market sale · S | −15,843 | $116.12 | −$1.84M | 18,682 |
| Maduck Sean | See Remarks | Oct 02 | Exercise / conversion · M | +24,587 | $8.27 | +$203K | 34,525 |
| Lyon Joseph Douglas | See Remarks | Oct 01 | Open-market sale · S | −810 | $115.40 | −$93.5K | 5,683 |
| Lyon Joseph Douglas | See Remarks | Oct 01 | Exercise / conversion · M | +810 | $13.56 | +$11K | 6,493 |
| Maduck Sean | See Remarks | Oct 01 | Open-market sale · S | −413 | $115.54 | −$47.7K | 9,938 |
| Maduck Sean | See Remarks | Oct 01 | Exercise / conversion · M | +413 | $8.27 | +$3.42K | 10,351 |
| Robb Gary Charles | Chief Business Officer | Sep 24 | Gift · G | +5,000 | — | — | 20,571 |
| Robb Gary Charles | Chief Business Officer | Sep 24 | Gift · G | +5,000 | — | — | 20,571 |
Loading...